uniQure NV (NASDAQ:QURE) fell 3.4% during trading on Monday . The stock traded as low as $8.20 and last traded at $8.41, with a volume of 110,615 shares trading hands. The stock had previously closed at $8.71.

Several research firms have commented on QURE. Jefferies Group restated a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Oppenheimer Holdings Inc. reiterated a “buy” rating on shares of uniQure NV in a research note on Tuesday, May 31st. Chardan Capital reiterated a “buy” rating on shares of uniQure NV in a research note on Thursday, April 14th. Leerink Swann reiterated a “buy” rating and set a $27.00 price objective (down previously from $48.00) on shares of uniQure NV in a research note on Wednesday, April 13th. Finally, Piper Jaffray Cos. reiterated a “buy” rating on shares of uniQure NV in a research note on Monday, June 13th. One analyst has rated the stock with a sell rating and ten have given a buy rating to the company. The company currently has a consensus rating of “Buy” and a consensus price target of $29.10.

The firm’s market cap is $204.76 million. The firm’s 50 day moving average price is $7.59 and its 200-day moving average price is $12.10.

uniQure NV (NASDAQ:QURE) last announced its quarterly earnings data on Tuesday, May 31st. The company reported ($0.93) EPS for the quarter, missing the Zacks’ consensus estimate of ($0.82) by $0.10. On average, equities analysts expect that uniQure NV will post ($3.48) earnings per share for the current year.

Uniqure NV is a pharmaceutical company based in the Netherlands. It is primarily engaged in the field of gene therapy for orphan diseases. The Company is focused on patients suffering from genetic or acquired diseases by directing the expression of a therapeutic protein or restoring the expression of a missing protein through a single administration.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.